NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating New Myeloma

NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with cyclophosphamide and dexamethasone may kill more cancer cells.> PURPOSE: This phase II trial is studying how well giving lenalidomide together with cyclophosphamide and dexamethasone works in treating patients with newly diagnosed multiple myeloma.

Sponsor

Mayo Clinic

Collaborator

National Cancer Institute (NCI)

Locations

United States, Arizona

United States, Minnesota

---

ClinicalTrials.gov Identifier: NCT00478218

Official Title: A Phase II Trial of Revlimid, Cyclophosphamide, and Dexamethasone in Patients With > Newly Diagnosed Active Multiple Myeloma

First Posted : May 24, 2007

https://clinicaltrials.gov/ct2/show/NCT00478218

---

Drug: cyclophosphamide

Drug: dexamethasone

Drug: lenalidomide

---

Am J Hematol; 2011

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial

CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy.

https://pubmed.ncbi.nlm.nih.gov/21630308/